Three drugmakers recently announced refunds to 340B covered entities, while two others announced NDC changes.

Lilly, Indivior, Kedrion to Refund 340B Covered Entities for Overcharges, Others Announce NDC Changes

July 22, 2025 Shannon Young, Associate Editor/Senior Writer 340B Report Views

Three drugmakers are offering refunds to 340B covered entities that purchased certain drugs between 2022 and 2025 following recalculations of [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!